Nasioudis D, et al. - Researchers determined the patterns of use and outcomes of adjuvant chemotherapy for patients diagnosed with FIGO stage I ovarian clear cell carcinoma (OCCC), using multivariate logistic regression, Kaplan-Meier curves, and multivariate Cox analysis. They used the National Cancer Database to select a cohort of patients diagnosed between 2004 and 2015 with OCCC. Further analysis was carried out in those with stage I disease who had primary surgery and underwent systematic lymphadenectomy (defined as at least 10 lymph nodes removed). A total of 1839 (79.1%) patients received adjuvant chemotherapy. Hospital type and location, patient age, disease sub-stage, and year of diagnosis were found to be independently related to the administration of chemotherapy. They found that adjuvant chemotherapy could be related to a survival benefit for patients with stage I OCCC.